Swiss National Bank held its stake in shares of Insys Therapeutics, Inc. (NASDAQ:INSY) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 35,900 shares of the specialty pharmaceutical company’s stock at the end of the first quarter. Swiss National Bank’s holdings in Insys Therapeutics were worth $377,000 as of its most recent SEC filing.
Other large investors have also made changes to their positions in the company. Norges Bank purchased a new position in shares of Insys Therapeutics during the fourth quarter valued at about $3,408,000. First Trust Advisors LP increased its position in shares of Insys Therapeutics by 105.3% in the first quarter. First Trust Advisors LP now owns 147,788 shares of the specialty pharmaceutical company’s stock valued at $1,553,000 after buying an additional 75,817 shares in the last quarter. Bowling Portfolio Management LLC purchased a new position in shares of Insys Therapeutics during the first quarter valued at about $655,000. Wells Fargo & Company MN increased its position in shares of Insys Therapeutics by 30.3% in the first quarter. Wells Fargo & Company MN now owns 27,541 shares of the specialty pharmaceutical company’s stock valued at $289,000 after buying an additional 6,407 shares in the last quarter. Finally, Bank of Montreal Can increased its position in shares of Insys Therapeutics by 215.3% in the first quarter. Bank of Montreal Can now owns 20,812 shares of the specialty pharmaceutical company’s stock valued at $219,000 after buying an additional 14,212 shares in the last quarter. Institutional investors and hedge funds own 28.15% of the company’s stock.
Shares of Insys Therapeutics, Inc. (NASDAQ:INSY) traded down 0.30% on Monday, reaching $9.97. 793,360 shares of the company were exchanged. The stock’s market capitalization is $719.09 million. Insys Therapeutics, Inc. has a 52 week low of $8.70 and a 52 week high of $19.96. The firm’s 50 day moving average price is $12.35 and its 200 day moving average price is $11.49.
Insys Therapeutics (NASDAQ:INSY) last released its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.12. The company had revenue of $42.60 million for the quarter, compared to the consensus estimate of $36.90 million. Insys Therapeutics had a negative net margin of 9.63% and a negative return on equity of 3.01%. Insys Therapeutics’s revenue was down 38.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 EPS. Equities research analysts anticipate that Insys Therapeutics, Inc. will post ($0.41) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Insys Therapeutics, Inc. (NASDAQ:INSY) Position Maintained by Swiss National Bank” was originally reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2017/08/08/swiss-national-bank-has-377000-position-in-insys-therapeutics-inc-nasdaqinsy-updated-updated.html.
Several research analysts have recently issued reports on INSY shares. Royal Bank Of Canada reiterated a “buy” rating and issued a $16.00 target price on shares of Insys Therapeutics in a research note on Friday, April 28th. Jefferies Group LLC reiterated a “buy” rating and issued a $14.00 target price on shares of Insys Therapeutics in a research note on Friday, June 9th. BidaskClub upgraded shares of Insys Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a research note on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $10.00 target price on shares of Insys Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.25.
In other Insys Therapeutics news, Director Rohit Vishnoi acquired 4,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was acquired at an average cost of $14.14 per share, for a total transaction of $56,560.00. Following the purchase, the director now owns 4,000 shares in the company, valued at approximately $56,560. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Saeed Motahari bought 5,400 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The stock was purchased at an average price of $11.10 per share, with a total value of $59,940.00. Following the completion of the purchase, the chief executive officer now owns 9,900 shares in the company, valued at $109,890. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 21,900 shares of company stock worth $268,090. 67.90% of the stock is owned by insiders.
About Insys Therapeutics
Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.
Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
